Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead price target raised to $120 from $105 at Bernstein
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Hosted on MSN11d
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.
Nasdaq16d
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after market close. The Zacks Consensus Estimate for sales and earnings is ...
rarediseaseadvisor23d
Seladelpar Leads to Clinically Meaningful Improvements in PBC
52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...
The Pharma Letter25d
FDA approves Ozempic for patients with diabetes and CKD
In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...